Design, synthesis and biological evaluation of novel macrocyclic derivatives bearing aniline pyrimidine scaffolds as EGFR-TKIs
作者:Yuhui Shen、Xiaofei Xiao、Peng Zhang、Qiang Wang、Xueyan Zhu、Yulei Yang、Yinbo Chen
DOI:10.1016/j.bmcl.2022.128970
日期:2022.11
Based on EGFR-TKI Osimertinib as lead compound, a series of novel macrocyclic derivatives bearing aniline pyrimidine scaffolds were designed and synthesized by macrocyclization. Their structures were identified by 1H NMR, 13C NMR, 19F NMR and HRMS. The pharmacological activities of the target compounds were tested and the preliminary structure–activity relationship was discussed. Among them, 17-membered
以EGFR-TKI奥希替尼为先导化合物,通过大环化方法设计合成了一系列新型的以苯胺嘧啶为支架的大环衍生物。它们的结构通过1 H NMR、13 C NMR、19 F NMR和HRMS鉴定。测试了目标化合物的药理活性,并讨论了初步的构效关系。其中,17元环化合物H1对EGFR L858R/T790M和EGFR d746-750/T790M的抑制活性最好,IC 50值分别为2.92 nM和0.34 nM。令人兴奋的是,17 元环化合物H7对 BaF3-EGFR del19/T790M细胞系具有最强的抗增殖活性(IC 50 = 0.035 µm),与奥希替尼 (IC 50 = 0.033 µm) 相媲美。